Altis enters strategic partnership with CN-Bio
The Next Big Thing in Pharma
Poster: Characterization of a novel human primary intestinal epithelial monolayer platform in response to a cytokine challenge
How Does Altis Envision the Future of the Pharma Industry?
Manuscript: Analysis of Interleukin 8 Secretion by a Stem-Cell-Derived Human Intestinal Epithelial Monolayer Platform
Poster: GB004 Exhibits Protective Effects Directly on Epithelial Cells Using Ex Vivo Organoid and Monolayer Cultures
Manuscript: Self-renewing Monolayer of Primary Colonic or Rectal Epithelial Cells
Manuscript: Evaluation of human primary intestinal monolayers for drug metabolizing capabilities
Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro
Poster: A Sensitive and Specific Human Primary Stem Cell-Based In Vitro Assay for Predicting The Gastrointestinal Toxicity Risk of Therapeutic Agents
Poster: A primary jejunum and primary hepatocyte multi-organ MPS: a promising tool for more predictive studies of human drug ADME and oral bioavailability
Altis Biosystems Appoints Jimmy Smedley, Ph.D. Chief Operating Officer
Manuscript: NSAID-Induced Leaky Gut Modeled Using Polarized Monolayers of Primary Human Intestinal Epithelial Cells
Poster: Characterization of biological variability in a stem cell-derived human intestinal epithelium model
Poster: Genomic evaluation of RepliGut Planar Jejunum in Response to metabolic Inducers
How Does Altis Biosystems Envision the Future of the Pharma/Biopharma Industry?
Assessing Drug-induced Gut Toxicity In Vitro
Predicting Clinical GI Safety Outcomes Using an in vitro Human Intestinal Epithelial Model
Poster Presented at ISSX/DMDG meeting – June 2023
A Novel, High-Throughput Platform to Characterize Novel IBD Therapeutics
Ready to Go With Your Gut?
Contact us to learn more about RepliGut® Model Kits and Services.